Cisplatin pharmacogenetics, DNA repair polymorphisms, and esophageal cancer outcomes.

ABSTRACT:

Objectives

Genetic variations or polymorphisms within genes of the nucleotide excision repair (NER) pathway alter DNA repair capacity. Reduced DNA repair (NER) capacity may result in tumors that are more susceptible to cisplatin chemotherapy, which functions by causing DNA damage. We investigated the potential predictive significance of functional NER single nucleotide polymorphisms in esophageal cancer patients treated with (n = 262) or without (n = 108) cisplatin.

Methods

Four NER polymorphisms XPD Asp312Asn; XPD Lys751Gln, ERCC1 8092C/A, and ERCC1 codon 118C/T were each assessed in polymorphism-cisplatin treatment interactions for overall survival (OS), with progression-free survival (PFS) as a secondary endpoint.

Results

No associations with ERCC1 118 were found.

SUBMITTER: Bradbury PA 

PROVIDER: S-EPMC3085844 | biostudies-literature | 2009 Aug

REPOSITORIES: biostudies-literature